A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement
- 7 October 2022
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (1) , 193-202
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- National Comprehensive Cancer Network Resectability Status for Pancreatic Carcinoma Predicts Overall SurvivalWorld Journal of Surgery, 2015
- Neoadjuvant Gemcitabine-based Accelerated Hyperfractionation Chemoradiotherapy for Patients with Borderline Resectable Pancreatic AdenocarcinomaJapanese Journal of Clinical Oncology, 2014
- Quality of Life in a Prospective, Multicenter Phase 2 Trial of Neoadjuvant Full-Dose Gemcitabine, Oxaliplatin, and Radiation in Patients With Resectable or Borderline Resectable Pancreatic AdenocarcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2014
- Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)Surgery, 2014
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus GemcitabineNew England Journal of Medicine, 2013
- Arterial Resection During Pancreatectomy for Pancreatic CancerAnnals of Surgery, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of DiseaseJournal of the American College of Surgeons, 2008
- Classification of Surgical ComplicationsAnnals of Surgery, 2004
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the PancreasArchives of Surgery, 1992